Innovative Clinical Perspectives for CIK Cells in Cancer Patients

被引：55

作者：

Introna, Martino ^{[1
]}

Correnti, Fabio ^{[1
]}

机构：

[1] ASST Papa Giovanni XXIII Bergamo, USS Ctr Cell Therapy G Lanzani, USC Ematol, I-24124 Bergamo, Italy

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2018年 / 19卷 / 02期

关键词：

CIK; NK; GvHD; INDUCED KILLER-CELLS; CD3(+)CD56(+) CYTOTOXIC-CELLS; CHRONIC MYELOID-LEUKEMIA; IN-VITRO CYTOTOXICITY; NK-T CELLS; DENDRITIC CELLS; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC TRANSPLANT; ANTITUMOR-ACTIVITY; ELDERLY-PATIENTS;

D O I：

10.3390/ijms19020358

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cytokine-induced killer (CIK) cells are T lymphocytes that have acquired, in vitro, following extensive manipulation by Interferon gamma (IFN-), OKT3 and Interleukin 2 (IL-2) addition, the expression of several Natural Killer (NK) cell-surface markers. CIK cells have a dual nature, due to the presence of functional TCR as well as NK molecules, even if the antitumoral activity can be traced back only to the NK-like structures (DNAM-1, NKG2D, NKp30 and CD56). In addition to antineoplastic activity in vitro and in several in-vivo models, CIK cells show very limited, if any, GvHD toxicity as well as a strong intratumoral homing. For all such reasons, CIK cells have been proposed and tested in many clinical trials in cancer patients both in autologous and allogeneic combinations, up to haploidentical mismatching. Indeed, genetic modification of CIK cells as well as the possibility of combining them with specific monoclonal antibodies will further expand the possibility of their clinical utilization.

引用

页数：14

共 60 条

[1] Expansion of cytotoxic CD3+CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation [J].

Alvarnas, JC ;

Linn, YC ;

Hope, EG ;

Negrin, RS .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (04) :216-222

[2] Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production [J].

Baker, J ;

Verneris, MR ;

Ito, M ;

Shizuru, JA ;

Negrin, RS .

BLOOD, 2001, 97 (10) :2923-2931

[3] Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia [J].

Biondi, Andrea ;

Magnani, Chiara F. ;

Tettamanti, Sarah ;

Gaipa, Giuseppe ;

Biagi, Ettore .

JOURNAL OF AUTOIMMUNITY, 2017, 85 :141-152

[4] Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages [J].

Diefenbach, A ;

Jamieson, AM ;

Liu, SD ;

Shastri, N ;

Raulet, DH .

NATURE IMMUNOLOGY, 2000, 1 (02) :119-126

[5] Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging [J].

Edinger, M ;

Cao, YA ;

Verneris, MR ;

Bachmann, MH ;

Contag, CH ;

Negrin, RS .

BLOOD, 2003, 101 (02) :640-648

[6] Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells [J].

Ferlazzo, G ;

Tsang, ML ;

Moretta, L ;

Melioli, G ;

Steinman, RM ;

Münz, C .

JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (03) :343-351

[7] Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes [J].

Franceschetti, Marta ;

Pievani, Alice ;

Borleri, Gianmaria ;

Vago, Luca ;

Fleischhauer, Katharina ;

Golay, Josee ;

Introna, Martino .

EXPERIMENTAL HEMATOLOGY, 2009, 37 (05) :616-628

[8] A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy [J].

Golay, Josee ;

D'Amico, Anna ;

Borleri, Gianmaria ;

Bonzi, Michela ;

Valgardsdottir, Rut ;

Alzani, Rachele ;

Cribioli, Sabrina ;

Albanese, Clara ;

Pesenti, Enrico ;

Finazzi, Maria Chiara ;

Quaresmini, Giulia ;

Nagorsen, Dirk ;

Introna, Martino ;

Rambaldi, Alessandro .

JOURNAL OF IMMUNOLOGY, 2014, 193 (09) :4739-4747

[9] Generation of CD3+CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer [J].

Hongeng, S ;

Petvises, S ;

Worapongpaiboon, S ;

Rerkamnuaychoke, B ;

Pakakasama, S ;

Jootar, S .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2003, 77 (02) :175-179

[10] Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC) [J].

Hontscha, C. ;

Borck, Y. ;

Zhou, H. ;

Messmer, D. ;

Schmidt-Wolf, I. G. H. .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (02) :305-310

← 1 2 3 4 5 6 →